B細胞リンパ腫の治療の世界市場

B細胞リンパ腫の治療の世界市場は2030年までに90億米ドルに達する見込み

2024年に64億米ドルと推定されるB細胞リンパ腫の治療の世界市場は、2024年から2030年にかけてCAGR 6.0％で成長し、2030年には90億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるDiffuse Large B細胞リンパ腫の治療は、CAGR 5.2％を記録し、分析期間終了までに22億米ドルに達すると予測されます。リンパ形質細胞性リンパ腫治療セグメントの成長率は、分析期間中CAGR 4.8％と推定されます。

米国市場は17億米ドルと推定、中国はCAGR9.3％で成長予測

米国のB細胞リンパ腫の治療市場は2024年に17億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに18億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.0％と5.8％と予測されています。欧州では、ドイツがCAGR 3.9%で成長すると予測されています。

世界のB細胞リンパ腫の治療市場- 主要動向と促進要因のまとめ

なぜB細胞リンパ腫の治療市場は精密治療、マルチライン戦略、長期的な疾病管理へと進化しているのか？

B細胞リンパ腫の治療は、精密医療、併用レジメン、免疫療法の革新により、進行性・非緩和性サブタイプの両方において、治療パラダイムが再構築され、大きな変革期を迎えています。非ホジキンリンパ腫の中で最も有病率の高いB細胞型（びまん性大細胞型B細胞リンパ腫（DLBCL）、濾胞性リンパ腫、マントル細胞リンパ腫を含む）は、分子型分類、治療歴、患者固有の危険因子に基づく高度に層別化されたアプローチが必要です。R-CHOPのような標準療法が第一選択レジメンの中心であり続けているが、再発抑制と持続的寛解に重点を置く傾向が強まり、治療法の多様化が急速に進んでいます。

初回治療後に再発する患者や難治性の患者も相当数存在するため、治療法は、標的薬剤、免疫療法、細胞ベースのプラットフォームなどを組み込んだ逐次的な多剤併用療法を特徴とするようになってきています。分子プロファイリングとバイオマーカー検査は、特にダブルヒット、トリプルヒット、ハイリスク細胞遺伝学的特徴、CD20陰性の患者に対する治療選択を導くために、治療アルゴリズムの早い段階で統合されつつあります。多くのサブグループで生存成績が改善するにつれて、長期的な病勢コントロールとQOLは、従来の奏効指標と並行して目標とされるようになってきています。

新たな治療プロトコールはまた、患者の併存疾患、治療忍容性、嗜好性を考慮した個別化治療モデルに合致しつつあります。このため、高齢者や虚弱な集団では、入院期間を短縮する外来対応の治療薬とともに、より負荷の少ないレジメンの使用が増加しています。これらのシフトは総体的に、最大限の忍容性を有するレジメンから、有効性、安全性、患者中心のバランスを考慮した戦略的な段階的治療への移行という、腫瘍学におけるより広範な進化を反映しています。

モノクローナル抗体、CAR-T療法、二重特異性T細胞エンゲイジャーは、どのように治療の選択肢を変えているのか？

モノクローナル抗体、特にリツキシマブ、オビヌツズマブ、オファツムマブなどの抗CD20薬は、依然としてB細胞リンパ腫の治療の基礎となっています。これらの薬剤は、新規の低分子化合物や化学療法剤との併用が増加しており、管理可能な毒性プロファイルを維持しながら、反応の深さを向上させています。ADCC（抗体依存性細胞傷害性）特性を強化した第2世代抗体も、再発または難治性（R/R）の状況で採用されつつあります。

キメラ抗原受容体T細胞（CAR-T）療法は、特にDLBCLや原発性縦隔B細胞リンパ腫などの侵攻性B細胞リンパ腫において、3次治療やサルベージ治療のプロトコルを再定義しつつあります。FDAが承認したaxicabtagene ciloleucelやtisagenlecleucelのような製品は、重篤な前治療患者において持続的な奏効を示しました。CAR-Tは、物流やコスト面での課題にもかかわらず、製造能力の拡大や有害事象管理プロトコルの改善に支えられ、より早期の治療ラインや橋渡し的薬剤との併用でますます検討されるようになってきています。

二重特異性T細胞エンゲイジャー（BiTE）は、個別化された細胞処理を必要とせず、細胞傷害性T細胞を悪性B細胞にリダイレクトする既製の免疫療法として台頭してきています。glofitamabやepcoritamabのようなCD3-CD20二重特異性薬剤は、臨床試験において、特にCAR-Tの適応のない患者やCAR-T後に再発した患者において、有望な効果を示しています。その良好な投与プロファイル（多くの場合、皮下または静脈内点滴）は、地域の腫瘍科設定や外来点滴センターにとって汎用性の高いツールとして位置づけられています。

どのようなパイプラインの革新、規制の加速、市場の力が長期的な成長軌道に影響を与えているか？

B細胞リンパ腫治療薬のパイプラインは強固で、BTK阻害剤、BCL-2阻害剤、PI3K阻害剤、新規抗体薬物複合体（ADC）などが含まれます。イブルチニブ、venetoclax、polatuzumab vedotinなどの治療薬はすでに再発／難治性の治療ラインに組み込まれており、新しい分子は選択性の改善、毒性の軽減、耐性メカニズムの克服を目指しています。標的治療薬と免疫療法または化学療法のバックボーンを組み合わせたコンビナトリアルレジメンは、複数のリンパ腫サブタイプにおいて標準治療経路を再構築する可能性を示しています。

規制機関は、特に再発/難治性疾患や遺伝学的に定義された高リスクコホートを対象とした、ニーズの高い治療法のための促進経路を促進しています。ブレークスルー指定、ローリング申請、適応試験デザインにより、画期的な治療法の市場投入までの時間が短縮される一方、臨床試験を超えた長期的転帰を検証するために実臨床のエビデンスが取り入れられるようになっています。このような動向は、希少なサブタイプやこれまで十分な治療を受けていなかった患者層に対する製薬企業の投資を促しています。

市場力学はまた、コスト抑制圧力、バリューベースの腫瘍学モデル、高コストの免疫療法に対する支払者の監視によって形成されています。メーカー各社は、革新的な価格戦略、アウトカムベースの償還モデル、患者アクセスプログラムの拡充などで対応しています。より多くの治療選択肢が商業化される中、投与経路、毒性プロファイル、コンパニオン診断薬との整合性に基づく差別化は、市場でのポジショニングにとって極めて重要です。成長するバイオシミラー市場とともに、進化する支払者と医療提供者の力学は、B細胞リンパ腫治療の採用軌道とライフサイクル戦略に影響を与え続けると思われます。

B細胞リンパ腫の治療市場の成長を促進する要因は何か？

B細胞リンパ腫の治療市場は、臨床革新、患者層別化、免疫療法の進歩が融合し、最前線と再発の両方の状況において管理アプローチを再定義することで拡大しています。オーダーメイドの治療戦略が従来の単剤療法を置き換え、生存期間を延長し、多様な患者集団のQOLを向上させています。

主な促進要因としては、CD20標的薬の適応拡大、CAR-T療法の早期治療ラインへの普及、二重特異性抗体の採用拡大、標的低分子化合物や生物製剤の強力な後期パイプラインなどが挙げられます。規制の加速化と支払者の進化も、次世代療法への迅速なアクセスと幅広い市場参入を可能にしています。

腫瘍学が臓器ベースからバイオマーカー主導のパラダイムに移行する中、B細胞リンパ腫の治療は、高精度免疫腫瘍学が、慢性血液悪性腫瘍を、現実の医療環境において、耐久性があり、管理可能な状態に変化させる代表的な例として登場する可能性はあるのだろうか。

セグメント

タイプ（びまん性大細胞型B細胞リンパ腫、リンパ形質細胞性リンパ腫、ヘアリー細胞白血病、原発性中枢神経系リンパ腫、原発性眼内リンパ腫、その他のタイプ）、エンドユーザー（病院、専門クリニック、在宅ヘルスケア、その他のエンドユーザー）、流通チャネル（直接販売、病院薬局、小売薬局、オンライン薬局、その他の流通チャネル）

調査対象企業の例（注目の41社）

• AbbVie Inc.
• ADC Therapeutics SA
• Amgen Inc.
• AstraZeneca PLC
• Bayer AG
• BeiGene Ltd.
• Bristol-Myers Squibb Co.
• Celltrion Healthcare Co.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Incyte Corporation
• Johnson & Johnson Services
• Kite Pharma, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Seagen Inc.
• Takeda Pharmaceutical Co.

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global B-Cell Lymphoma Treatment Market to Reach US$9.0 Billion by 2030

The global market for B-Cell Lymphoma Treatment estimated at US$6.4 Billion in the year 2024, is expected to reach US$9.0 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Diffuse Large B-Cell Lymphoma Treatment, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Lymphoplasmacytic Lymphoma Treatment segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 9.3% CAGR

The B-Cell Lymphoma Treatment market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 9.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global B-Cell Lymphoma Treatment Market - Key Trends & Drivers Summarized

Why Is the B-Cell Lymphoma Treatment Landscape Evolving Toward Precision Therapies, Multi-Line Strategies, and Long-Term Disease Control?

B-cell lymphoma treatment is undergoing significant transformation as precision medicine, combination regimens, and immunotherapeutic innovations reshape care paradigms across both aggressive and indolent subtypes. As the most prevalent form of non-Hodgkin lymphoma, B-cell variants-including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and mantle cell lymphoma-require highly stratified approaches based on molecular subtyping, treatment history, and patient-specific risk factors. Standard therapies such as R-CHOP continue to anchor first-line regimens, but a growing emphasis on relapse mitigation and durable remission is prompting rapid therapeutic diversification.

With a substantial subset of patients relapsing after initial therapy or presenting with refractory disease, the treatment landscape is increasingly characterized by sequential, multi-line strategies that incorporate targeted agents, immunotherapies, and cell-based platforms. Molecular profiling and biomarker testing are being integrated earlier in the treatment algorithm to guide therapy selection-particularly for patients with double- or triple-hit genetic features, high-risk cytogenetics, or CD20-negativity. As survival outcomes improve in many subgroups, long-term disease control and quality of life are becoming parallel goals alongside traditional response metrics.

Emerging treatment protocols are also aligning with personalized care models that account for patient comorbidities, treatment tolerability, and preference. This has led to the increasing use of less-intensive regimens in elderly or frail populations, along with outpatient-compatible therapeutics that reduce hospitalization time. Collectively, these shifts reflect a broader evolution in oncology: moving beyond maximum tolerable regimens to strategically layered therapies that balance efficacy, safety, and patient-centricity.

How Are Monoclonal Antibodies, CAR-T Therapies, and Bispecific T-Cell Engagers Reshaping the Treatment Arsenal?

Monoclonal antibodies remain foundational to B-cell lymphoma treatment, particularly anti-CD20 agents such as rituximab, obinutuzumab, and ofatumumab. These agents are increasingly used in combination with novel small molecules or chemotherapeutics, improving depth of response while maintaining manageable toxicity profiles. Second-generation antibodies with enhanced ADCC (antibody-dependent cellular cytotoxicity) properties are also being adopted in relapsed or refractory (R/R) settings.

Chimeric antigen receptor T-cell (CAR-T) therapies are redefining third-line and salvage treatment protocols, especially in aggressive B-cell lymphomas such as DLBCL and primary mediastinal B-cell lymphoma. FDA-approved products like axicabtagene ciloleucel and tisagenlecleucel have demonstrated durable responses in heavily pretreated patients. Despite logistical and cost challenges, CAR-T is being increasingly explored in earlier lines of therapy and in combination with bridging agents, supported by expanding manufacturing capabilities and improved adverse event management protocols.

Bispecific T-cell engagers (BiTEs) are emerging as off-the-shelf immunotherapies that redirect cytotoxic T cells to malignant B cells without the need for individualized cell processing. CD3-CD20 bispecifics such as glofitamab and epcoritamab have shown encouraging efficacy in clinical trials, particularly in patients ineligible for CAR-T or with disease relapse post-CAR-T. Their favorable administration profile-often as subcutaneous or intravenous infusions-positions them as a versatile tool for community oncology settings and outpatient infusion centers.

Which Pipeline Innovations, Regulatory Accelerations, and Market Forces Are Influencing Long-Term Growth Trajectories?

The pipeline for B-cell lymphoma therapeutics is robust, encompassing BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, and novel antibody-drug conjugates (ADCs). Agents such as ibrutinib, venetoclax, and polatuzumab vedotin are already integrated into relapsed/refractory treatment lines, while newer molecules aim to improve selectivity, reduce toxicity, and overcome resistance mechanisms. Combinatorial regimens pairing targeted agents with immunotherapies or chemotherapy backbones are showing promise in reshaping standard-of-care pathways across multiple lymphoma subtypes.

Regulatory agencies are facilitating accelerated pathways for high-need therapies, particularly those targeting relapsed/refractory disease or genetically defined high-risk cohorts. Breakthrough designations, rolling submissions, and adaptive trial designs are enabling faster time-to-market for transformative therapies, while real-world evidence is being incorporated to validate long-term outcomes beyond clinical trials. These trends are encouraging pharmaceutical investment in rare subtypes and previously underserved patient segments.

Market dynamics are also being shaped by cost-containment pressures, value-based oncology models, and payer scrutiny over high-cost immunotherapies. Manufacturers are responding with innovative pricing strategies, outcome-based reimbursement models, and expanded patient access programs. As more treatment options enter the commercial landscape, differentiation based on administration route, toxicity profile, and companion diagnostic alignment will be critical for market positioning. The evolving payer-provider dynamic, along with maturing biosimilar markets, will continue to influence adoption trajectories and lifecycle strategies for B-cell lymphoma treatments.

What Are the Factors Driving Growth in the B-Cell Lymphoma Treatment Market?

The B-cell lymphoma treatment market is expanding as clinical innovation, patient stratification, and immunotherapeutic advancement converge to redefine management approaches across both front-line and relapsed settings. Tailored treatment strategies are displacing legacy monotherapies, extending survival, and improving quality of life for a diverse and growing patient population.

Key growth drivers include expanded indications for CD20-targeting agents, CAR-T therapy diffusion into earlier treatment lines, increasing uptake of bispecific antibodies, and a strong late-stage pipeline of targeted small molecules and biologics. Regulatory acceleration and payer evolution are also enabling faster access and broader market reach for next-generation therapies.

As oncology shifts from organ-based to biomarker-led paradigms, could B-cell lymphoma treatment emerge as a leading example of how precision immuno-oncology transforms chronic hematologic malignancies into durable, manageable conditions across real-world care settings?

SCOPE OF STUDY:

The report analyzes the B-Cell Lymphoma Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma, Other Types); End-Use (Hospitals, Specialty Clinics, Home Healthcare, Other End-Uses); Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• AbbVie Inc.
• ADC Therapeutics SA
• Amgen Inc.
• AstraZeneca PLC
• Bayer AG
• BeiGene Ltd.
• Bristol-Myers Squibb Co.
• Celltrion Healthcare Co.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Incyte Corporation
• Johnson & Johnson Services
• Kite Pharma, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Seagen Inc.
• Takeda Pharmaceutical Co.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • B-Cell Lymphoma Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of B-Cell Lymphomas Throws the Spotlight on Targeted Therapeutics and Immunotherapy
  • Growth in Monoclonal Antibodies and CAR-T Cell Therapies Spurs Market Evolution in Hematologic Oncology
  • OEM Focus on CD19, CD20, and CD22 Targets Strengthens Precision in B-Cell Lymphoma Intervention
  • Expansion of Indolent and Aggressive Lymphoma Subtype-Specific Treatments Enhances Therapy Personalization
  • Adoption of Companion Diagnostics and Minimal Residual Disease (MRD) Monitoring Supports Therapy Optimization
  • Increased Investment in Bispecific Antibodies and Immune Checkpoint Inhibitors Diversifies Pipeline Options
  • Global Expansion of Cell Therapy Manufacturing Infrastructure Enhances Patient Access and Scalability
  • Rising Clinical Trial Enrollments and Academic-Industry Collaborations Fuel Research Across Lymphoma Subtypes
  • Digital Health Tools for Patient Monitoring and Adherence Strengthen Outcomes in Outpatient Settings
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World B-Cell Lymphoma Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for B-Cell Lymphoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for B-Cell Lymphoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Diffuse Large B-Cell Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Diffuse Large B-Cell Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Diffuse Large B-Cell Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Lymphoplasmacytic Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Lymphoplasmacytic Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Lymphoplasmacytic Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hairy Cell Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hairy Cell Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Hairy Cell Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Primary Central Nervous System Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Primary Central Nervous System Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Primary Central Nervous System Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Primary Intraocular Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Primary Intraocular Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Primary Intraocular Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Home Healthcare by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Home Healthcare by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Home Healthcare by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Direct Tender by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Direct Tender by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Direct Tender by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • B-Cell Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• JAPAN
  • B-Cell Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• CHINA
  • B-Cell Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• EUROPE
  • B-Cell Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for B-Cell Lymphoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for B-Cell Lymphoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• FRANCE
  • B-Cell Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 98: France Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• GERMANY
  • B-Cell Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 107: Germany Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 116: Italy Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • B-Cell Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 125: UK Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 134: Spain Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 140: Spain Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 143: Russia Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 149: Russia Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • B-Cell Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for B-Cell Lymphoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for B-Cell Lymphoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• AUSTRALIA
  • B-Cell Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 173: Australia Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 179: Australia Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• INDIA
  • B-Cell Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 182: India Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 188: India Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • B-Cell Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for B-Cell Lymphoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for B-Cell Lymphoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • B-Cell Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for B-Cell Lymphoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for B-Cell Lymphoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 269: Iran Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 275: Iran Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 278: Israel Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 284: Israel Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 296: UAE Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 302: UAE Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
• AFRICA
  • B-Cell Lymphoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 314: Africa Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for B-Cell Lymphoma Treatment by Type - Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for B-Cell Lymphoma Treatment by Type - Percentage Breakdown of Value Sales for Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma and Other Types for the Years 2015, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for B-Cell Lymphoma Treatment by End-Use - Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for B-Cell Lymphoma Treatment by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals, Specialty Clinics and Home Healthcare for the Years 2015, 2025 & 2030
  • TABLE 320: Africa Recent Past, Current & Future Analysis for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for B-Cell Lymphoma Treatment by Distribution Channel - Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for B-Cell Lymphoma Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION